P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.

View in: PubMed

subject areas

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
Cyclosporins
Cytarabine
Daunorubicin
Etoposide
Female
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Remission Induction
Survival Rate
Treatment Outcome
Young Adult

authors with profiles

Wendy Stock
James W. Vardiman
Richard A. Larson